Combinatorial immunotherapy of N-803 (IL-15 superagonist) and dinutuximab with ex vivo expanded natural killer cells significantly enhances in vitro cytotoxicity against GD2+pediatric solid tumors and in vivo survival of xenografted immunodeficient NSG mice
Abstract
Children with recurrent and/or metastatic osteosarcoma (OS), neuroblastoma (NB) and glioblastoma multiforme (GBM) have a dismal event-free survival (+NB post autologous stem cell transplantation and enhanced natural killer (NK) cell-mediated antibody-dependent cell cytotoxicity. Thus, approaches to increase NK cell number and activity, improve persistence and trafficking, and enhance tumor targeting may further improve the clinical benefit of dinutuximab. N-803 is a superagonist of an interleukin-15 (IL-15) variant bound to an IL-15 receptor alpha Su-Fc fusion with enhanced biological activity.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Jul 01, 2021
- Source ID
- 10.1136/jitc-2020-002267
Entities
People
- Dean A. Lee
- Gaurav Nayyar
- Jeffrey T Safrit
- Jeremy M. Rosenblum
- Mitchell S Cairo
- Patrick Soon-shiong
- Susiyan Jiang
- Yaya Chu
Organizations
- National Institutes of Health
- New York Medical College
- Pediatric Cancer Research Foundation
- United States Department of Defense